Feeling Patent Pain, Eli Lilly Places Hopes on Pipeline Prosperity in 2014

Eli Lilly is hoping to win several drug approvals next year to weather expiring patents, but for now plans to cut back on operating expenses to stay competitive. Sluggish growth in certain emerging markets has put a damper on sales, the pharma giant says. The new cost-cutting plan comes despite Lilly having the strongest pipeline in the company’s 137-year history, with 13 candidates in Phase III trials or in regulatory review.
Washington Drug Letter